Moving beyond anti-aquaporin-4 antibodies: emerging biomarkers in the spectrum of neuromyelitis optica

References

• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. .
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Guo Y, Popescu BF, et al. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24(1):83–97.
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535–544.
   PubMed Web of Science ®Google Scholar
• Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88(2):137–145.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–2124.
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Qiu W, et al. Tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorders (TANGO): a head-to-head comparative study. 2019. ECTRIMS Online Library
   Google Scholar
• Traboulsee AL, Greenberg B, Bennett JL, et al. Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): results from SAkuraStar, a double-blind placebo-controlled Phase 3 clinical study. J Neurol Sci. ECTRIMS Online Library 2019;405: 171.
   Web of Science ®Google Scholar
• Kim SH, Hyun JW, Joung A, et al. Occurrence of asymptomatic acute neuromyelitis optica spectrum disorder-typical brain lesions during an attack of optic neuritis or myelitis. PloS One. 2016;11(12):e0167783.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–2112. .
   PubMed Web of Science ®Google Scholar
• Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007;69(24):2221–2231.
   PubMed Web of Science ®Google Scholar
• Ruiz-Gaviria R, Baracaldo I, Castaneda C, et al. Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: A meta-analysis. Mult Scler Relat Disord. 2015;4(4):345–349.
   PubMed Web of Science ®Google Scholar
• Jarius S, Franciotta D, Paul F, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010;7(1):52.
   PubMedGoogle Scholar
• Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(11):3072–3080.
   PubMedGoogle Scholar
• Shaygannejad V, Fayyazi E, Badihian S, et al. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. J Neurol. 2019;266(3):642–650.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Kim SH, Schmidt F, et al. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler. 2018;24(13):1737–1742.
   PubMed Web of Science ®Google Scholar
• Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310–1315.
   PubMed Web of Science ®Google Scholar
• Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem. 1999;72(1):1–9.
   PubMed Web of Science ®Google Scholar
• Brunner C, Lassmann H, Waehneldt TV, et al. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2ʹ,3ʹ-cyclic nucleotide 3ʹ-phosphodiesterase in the CNS of adult rats. J Neurochem. 1989;52(1):296–304.
   PubMed Web of Science ®Google Scholar
• Johns TG, Bernard CC. Binding of complement component Clq to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol Immunol. 1997;34(1):33–38.
   PubMed Web of Science ®Google Scholar
• Mariotto S, Ferrari S, Monaco S, et al. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol. 2017;264(12):2420–2430.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016;15(4):307–324.
   PubMed Web of Science ®Google Scholar
• Spadaro M, Gerdes LA, Mayer MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol. 2015;2(3):295–301.
   PubMed Web of Science ®Google Scholar
• Jarius S, Metz I, Konig FB, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016;22(12):1541–1549.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Jaunmuktane Z, Mummery C, et al. Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD. Neurology. 2016;87(2):229–231.
   PubMed Web of Science ®Google Scholar
• Weber MS, Derfuss T, Metz I, et al. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord. 2018;11:1756286418762083.
   Web of Science ®Google Scholar
• Jarius S, Paul F, Aktas O, et al., MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 15(1): 134. 2018.
   PubMedGoogle Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13(1):279.
   PubMedGoogle Scholar
• Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90(21):e1858–e1869.
   PubMed Web of Science ®Google Scholar
• Durozard P, Rico A, Boutiere C, et al., Comparison of the response to rituximab between Myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol. 87(2): 256–266. 2020.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–1132.
   PubMed Web of Science ®Google Scholar
• Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133–1141.
   PubMed Web of Science ®Google Scholar
• Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflammation allergy drug targets. 2012;11(2):159–168.
   PubMedGoogle Scholar
• Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–1835.
   PubMed Web of Science ®Google Scholar
• Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13(10):1173–1175.
   PubMed Web of Science ®Google Scholar
• Carlson T, Kroenke M, Rao P, et al. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med. 2008;205(4):811–823.
   PubMed Web of Science ®Google Scholar
• Wang HH, Dai YQ, Qiu W, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011;18(10):1313–1317.
   PubMed Web of Science ®Google Scholar
• Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005;128(5):988–1002.
   PubMedGoogle Scholar
• Hou MM, Li YF, He LL, et al. Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis. Int Immunopharmacol. 2019;75:105793.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang H, Long Y, et al. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2011;234(1–2):155–160.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Tateishi T, Isobe N, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PloS One. 2013;8(4):e61835.
   PubMed Web of Science ®Google Scholar
• Axtell RC, Raman C. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev. 2012;248(1):23–35.
   PubMedGoogle Scholar
• Okada K, Matsushita T, Kira J, et al. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology. 2010;74(2):177–178.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Zhong X, et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol. 2012;32(5):1007–1011.
   PubMed Web of Science ®Google Scholar
• Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012;72(1):53–64.
   PubMed Web of Science ®Google Scholar
• Qi H. T follicular helper cells in space-time. Nat Rev Immunol. 2016;16(10):612–625.
   PubMed Web of Science ®Google Scholar
• Schmitt N, Bentebibel SE, Ueno H. Phenotype and functions of memory Tfh cells in human blood. Trends Immunol. 2014;35(9):436–442.
   PubMed Web of Science ®Google Scholar
• Dias ASO, Sacramento PM, Lopes LM, et al. TLR-2 and TLR-4 agonists favor expansion of CD4(+) T cell subsets implicated in the severity of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019;34:66–76.
   PubMed Web of Science ®Google Scholar
• Linhares UC, Schiavoni PB, Barros PO, et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol. 2013;33(1):179–189.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16(12):1443–1452.
   PubMed Web of Science ®Google Scholar
• Monteiro C, Fernandes G, Kasahara TM, et al. The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders. J Neuroimmunol. 2019;330:12–18.
   PubMed Web of Science ®Google Scholar
• Xue Q, Li X, Gu Y, et al. Unbalanced expression of ICOS and PD-1 in patients with neuromyelitis optica spectrum disorder. Sci Rep. 2019;9(1):14130.
   PubMedGoogle Scholar
• Morita R, Schmitt N, Bentebibel SE, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108–121.
   PubMed Web of Science ®Google Scholar
• Li YJ, Zhang F, Qi Y, et al. Association of circulating follicular helper T cells with disease course of NMO spectrum disorders. J Neuroimmunol. 2015;278:239–246.
   PubMed Web of Science ®Google Scholar
• Fan X, Jiang Y, Han J, et al. Circulating memory T follicular helper cells in patients with neuromyelitis optica/neuromyelitis optica spectrum disorders. Mediators Inflamm. 2016;2016:3678152.
   PubMed Web of Science ®Google Scholar
• Zhao C, Li HZ, Zhao DD, et al. Increased circulating T follicular helper cells are inhibited by rituximab in neuromyelitis optica spectrum disorder. Front Neurol. 2017;8:104.
   PubMed Web of Science ®Google Scholar
• Le Coz C, Joublin A, Pasquali JL, et al. Circulating TFH subset distribution is strongly affected in lupus patients with an active disease. PloS One. 2013;8(9):e75319.
   PubMed Web of Science ®Google Scholar
• Wen Y, Yang B, Lu J, et al. Imbalance of circulating CD4(+)CXCR5(+)FOXP3(+) Tfr-like cells and CD4(+)CXCR5(+)FOXP3(-) Tfh-like cells in myasthenia gravis. Neurosci Lett. 2016;630:176–182.
   PubMed Web of Science ®Google Scholar
• Nicolas P, Ruiz A, Cobo-Calvo A, et al. The balance in T follicular helper cell subsets is altered in neuromyelitis optica spectrum disorder patients and restored by rituximab. Front Immunol. 2019;10:2686.
   PubMed Web of Science ®Google Scholar
• Sabatino JJ Jr., Probstel AK, Zamvil SS. B cells in autoimmune and neurodegenerative central nervous system diseases. Nat Rev Neurosci. 2019;20:728–745.
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985;314(6011):537–539.
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3(10):944–950.
   PubMed Web of Science ®Google Scholar
• Cho EB, Cho HJ, Seok JM, et al. The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder. Neurol Sci. 2018;39(3):543–549.
   PubMed Web of Science ®Google Scholar
• Murakami M, Kamimura D, Hirano T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity. 2019;50(4):812–831.
   PubMed Web of Science ®Google Scholar
• Chihara N, Aranami T, Sato W, et al., Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA. 108(9): 3701–3706. 2011.
   PubMed Web of Science ®Google Scholar
• Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66(5):617–629.
   PubMed Web of Science ®Google Scholar
• Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, et al. The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives. Int J Mol Sci. 2016;17(3):273.
   PubMed Web of Science ®Google Scholar
• Tuzun E, Kurtuncu M, Turkoglu R, et al. Enhanced complement consumption in neuromyelitis optica and Behcet’s disease patients. J Neuroimmunol. 2011;233(1–2):211–215.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Wang C, et al. Increased soluble C5b-9 in CSF of neuromyelitis optica. Scand J Immunol. 2014;79(2):127–130.
   PubMed Web of Science ®Google Scholar
• Kuroda H, Fujihara K, Takano R, et al. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol. 2013;254(1–2):178–182.
   PubMed Web of Science ®Google Scholar
• Hakobyan S, Luppe S, Evans DR, et al., Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Mult Scler. 23(7): 946–955. 2017.
   PubMed Web of Science ®Google Scholar
• Veszeli N, Fust G, Csuka D, et al. A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission. Mol Immunol. 2014;57(2):200–209.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306(1–2):82–90.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Hogancamp WF, O’Brien PC, et al. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53(5):1107–1114.
   PubMed Web of Science ®Google Scholar
• Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology. 2004;63(12):2363–2370.
   PubMed Web of Science ®Google Scholar
• Tong Y, Yang T, Wang J, et al. Elevated plasma chemokines for eosinophils in neuromyelitis optica spectrum disorders during remission. Front Neurol. 2018;9:44.
   PubMed Web of Science ®Google Scholar
• Michael BD, Elsone L, Griffiths MJ, et al. Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms - a pilot study. Cytokine. 2013;64(1):90–96.
   PubMed Web of Science ®Google Scholar
• Melamed E, Levy M, Waters PJ, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflammation. 2015;2(4):e134.
   PubMed Web of Science ®Google Scholar
• Takano R, Misu T, Takahashi T, et al., Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 75(3): 208–216. 2010.
   PubMed Web of Science ®Google Scholar
• Misu T, Takano R, Fujihara K, et al. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry. 2009;80(5):575–577.
   PubMed Web of Science ®Google Scholar
• Wei Y, Chang H, Li X, et al. CSF-S100B is a potential candidate biomarker for neuromyelitis optica spectrum disorders. Biomed Res Int. 2018;2018:5381239.
   PubMed Web of Science ®Google Scholar
• Kaneko K, Sato DK, Nakashima I, et al., Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry. 87(11): 1257–1259. 2016.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Nakamura Y, Michalak Z, et al., Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 93(13): e1299–e1311. 2019.
   PubMed Web of Science ®Google Scholar
• Petzold A, Woodhall M, Khaleeli Z, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. J Neurol Neurosurg Psychiatry. 2019;90(9):1021–1026.
   PubMed Web of Science ®Google Scholar
• Tzartos JS, Stergiou C, Kilidireas K, et al. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. PloS One. 2013;8(9):e74773.
   PubMed Web of Science ®Google Scholar
• Long Y, Zheng Y, Shan F, et al. Development of a cell-based assay for the detection of anti-aquaporin 1 antibodies in neuromyelitis optica spectrum disorders. J Neuroimmunol. 2014;273(1–2):103–110.
   PubMed Web of Science ®Google Scholar
• Sanchez Gomar I, Diaz Sanchez M, Ucles Sanchez AJ, et al. Comparative analysis for the presence of IgG anti-aquaporin-1 in patients with NMO-spectrum disorders. Int J Mol Sci. 2016;17(8):1195.
   PubMed Web of Science ®Google Scholar
• Schanda K, Waters P, Holzer H, et al. Antibodies to aquaporin-1 are not present in neuromyelitis optica. Neurol Neuroimmunol Neuroinflammation. 2015;2(6):e160.
   PubMedGoogle Scholar
• Fang B, McKeon A, Hinson SR, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol. 2016;73(11):1297–1307.
   PubMed Web of Science ®Google Scholar
• Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol. 2017;81(2):298–309.
   PubMed Web of Science ®Google Scholar
• Yang X, Xu H, Ding M, et al. Overlapping autoimmune syndromes in patients with glial fibrillary acidic protein antibodies. Front Neurol. 2018;9:251.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Aksamit AJ, McKeon A, et al. Optic disc edema in glial fibrillary acidic protein autoantibody-positive meningoencephalitis. J Neuro-ophthalmol. 2018;38(3):276–281.
   PubMed Web of Science ®Google Scholar
• Shimizu F, Schaller KL, Owens GP, et al. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci Transl Med. 2017;9(397):eaai9111.
   PubMed Web of Science ®Google Scholar
• Shimizu F, Takeshita Y, Hamamoto Y, et al. GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica. Ann Clin Transl Neurol. 2019;6(10):2079–2087.
   PubMed Web of Science ®Google Scholar
• Shimizu F, Takeshita Y, Sano Y, et al. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain. 2019;142(8):2253–2264.
   PubMedGoogle Scholar
• Arru G, Sechi E, Mariotto S, et al. Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD. J Neuroimmunol. 2020;338:577110.
   PubMed Web of Science ®Google Scholar
• Arru G, Sechi E, Mariotto S, et al. Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder. Mult Scler J Exp Transl Clin. 2017;3(4):2055217317742425.
   Google Scholar
• Kawamura N, Yamasaki R, Yonekawa T, et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology. 2013;81(8):714–722.
   PubMed Web of Science ®Google Scholar
• Jia K, Zhang X, Zhang LJ, et al. Anti-neurofascin-155 antibody-positive neuromyelitis optica spectrum disorders. J Neurol Sci. 2019;398:16–18.
   PubMed Web of Science ®Google Scholar
• Masaki K, Suzuki SO, Matsushita T, et al. Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica. PloS One. 2013;8(8):e72919.
   PubMed Web of Science ®Google Scholar
• Masaki K, Suzuki SO, Matsushita T, et al. Extensive loss of connexins in Balo’s disease: evidence for an auto-antibody-independent astrocytopathy via impaired astrocyte-oligodendrocyte/myelin interaction. Acta Neuropathol. 2012;123(6):887–900.
   PubMed Web of Science ®Google Scholar
• Keegan BM, Pittock SJ, Lennon VA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol. 2008;63(4):531–534.
   PubMed Web of Science ®Google Scholar
• Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2):146–154.
   PubMed Web of Science ®Google Scholar
• Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003;54(1):38–50.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wandinger KP, Borowski K, et al. Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg. 2012;114(4):331–335.
   PubMed Web of Science ®Google Scholar
• Yang HK, Woo SJ, Park WY, et al. Paraneoplastic neuromyelitis optica associated with ANNA-1 antibodies in invasive thymoma. BMC Ophthalmol. 2014;14(1):106.
   PubMedGoogle Scholar
• Cai G, He D, Chu L, et al. Paraneoplastic neuromyelitis optica spectrum disorders: three new cases and a review of the literature. Int J Neurosci. 2016;126(7):660–668.
   PubMed Web of Science ®Google Scholar
• Fan S, Xu Y, Ren H, et al. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Mult Scler Relat Disord. 2018;20:144–152.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012;18(1):5–10.
   PubMed Web of Science ®Google Scholar
• Wang X, Yi H, Liu J, et al. Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders. J Neurol Sci. 2016;366:3–7.
   PubMed Web of Science ®Google Scholar
• Leite MI, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012;78(20):1601–1607.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65(1):78–83.
   PubMedGoogle Scholar
• Shahmohammadi S, Doosti R, Shahmohammadi A, et al. Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review. Mult Scler Relat Disord. 2019;27:350–363.
   PubMed Web of Science ®Google Scholar
• Harada T, Ohashi T, Harada C, et al. A case of bilateral optic neuropathy and recurrent transverse myelopathy associated with perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA). J Neuro-ophthalmol. 1997;17(4):254–256.
   PubMed Web of Science ®Google Scholar
• Karussis D, Leker RR, Ashkenazi A, et al. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol. 1998;44(4):629–634.
   PubMed Web of Science ®Google Scholar
• Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(6):1834–1849.
   PubMedGoogle Scholar
• Lim YM, Pyun SY, Lim HT, et al. First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis. Neurol Sci. 2014;35(5):781–783.
   PubMed Web of Science ®Google Scholar
• Vabanesi M, Pisa M, Guerrieri S, et al. In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis. Sci Rep. 2019;9(1):10371.
   PubMedGoogle Scholar
• Shen T, You Y, Arunachalam S, et al., Differing structural and functional patterns of optic nerve damage in multiple sclerosis and neuromyelitis optica spectrum disorder. Ophthalmology. 126(3): 445–453. 2019.
   PubMed Web of Science ®Google Scholar
• Sotirchos ES, Saidha S, Byraiah G, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology. 2013;80(15):1406–1414.
   PubMed Web of Science ®Google Scholar
• Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology. 2009;73(4):302–308.
   PubMed Web of Science ®Google Scholar
• Bennett JL, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler. 2015;21(6):678–688.
   PubMed Web of Science ®Google Scholar
• Schneider E, Zimmermann H, Oberwahrenbrock T, et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PloS One. 2013;8(6):e66151.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Nakazawa T, Doi H, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefe’s Arch Clin Exp Ophthalmol. 2010;248(12):1777–1785.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Havla J, Roca-Fernandez A, et al., Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry. 89(12): 1259–1265. 2018.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Outteryck O, Knier B, et al. Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. J Neuroinflammation. 2019;16(1):154.
   PubMedGoogle Scholar
• Pisa M, Ratti F, Vabanesi M, et al. Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography. Mult Scler. 2019;1352458519861603.
   Web of Science ®Google Scholar
• Oertel FC, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflammation. 2017;4(3):e334.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Nakashima I. Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy? Neurol Neuroimmunol Neuroinflammation. 2017;4(3):e347.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhou L, ZhangBao J, et al., Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. Br J Ophthalmol. 103(6): 789–796. 2019.
   PubMed Web of Science ®Google Scholar
• Kwapong WR, Peng C, He Z, et al. Altered macular microvasculature in neuromyelitis optica spectrum disorders. Am J Ophthalmol. 2018;192:47–55.
   PubMed Web of Science ®Google Scholar
• Feucht N, Maier M, Lepennetier G, et al. Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis. Mult Scler. 2019;25(2):224–234.
   PubMed Web of Science ®Google Scholar
• Wang X, Jia Y, Spain R, et al. Optical coherence tomography angiography of optic nerve head and parafovea in multiple sclerosis. Br J Ophthalmol. 2014;98(10):1368–1373.
   PubMed Web of Science ®Google Scholar
• Ohnari K, Okada K, Takahashi T, et al. Evoked potentials are useful for diagnosis of neuromyelitis optica spectrum disorder. J Neurol Sci. 2016;364:97–101.
   PubMed Web of Science ®Google Scholar
• Kim S, Park J, Kwon BS, et al. Radiculopathy in neuromyelitis optica. How does anti-AQP4 Ab involve PNS? Mult Scler Relat Disord. 2017;18:77–81.
   PubMed Web of Science ®Google Scholar
• Takai Y, Misu T, Nakashima I, et al. Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody. Neurology. 2012;79(17):1826–1828.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Paul F, Lana-Peixoto MA, et al., MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 84(11): 1165–1173. 2015.
   PubMed Web of Science ®Google Scholar
• Cacciaguerra L, Meani A, Mesaros S, et al. Brain and cord imaging features in neuromyelitis optica spectrum disorders. Ann Neurol. 2019;85(3):371–384.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63(7):964–968.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–1489.
   PubMed Web of Science ®Google Scholar
• Yonezu T, Ito S, Mori M, et al. “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler. 2014;20(3):331–337.
   PubMed Web of Science ®Google Scholar
• Asgari N, Skejoe HP, Lillevang ST, et al. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol. 2013;13(1):33.
   PubMedGoogle Scholar
• Murchison A, Kitley J, Leite MI, et al. Predictive value of MRI parameters in severity and recovery of first-episode myelitis in aquaporin-4 antibody disease. J Neurol Sci. 2015;355(1–2):49–53.
   PubMed Web of Science ®Google Scholar
• Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011;76(14):1229–1237.
   PubMed Web of Science ®Google Scholar
• Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler. 2010;16(10):1229–1236.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Misu T, Fujihara K, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler. 2009;15(6):695–700.
   PubMedGoogle Scholar
• Makino T, Ito S, Mori M, et al. Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Mult Scler. 2013;19(3):308–315.
   PubMed Web of Science ®Google Scholar
• Ito S, Mori M, Makino T, et al. “Cloud-like enhancement” is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol. 2009;66(3):425–428.
   PubMed Web of Science ®Google Scholar
• Banker P, Sonni S, Kister I, et al. Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler. 2012;18(7):1050–1053.
   PubMed Web of Science ®Google Scholar
• Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72(1):81–87.
   PubMed Web of Science ®Google Scholar
• Matthews L, Marasco R, Jenkinson M, et al., Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 80(14): 1330–1337. 2013.
   PubMed Web of Science ®Google Scholar
• Jurynczyk M, Tackley G, Kong Y, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry. 2017;88(2):132–136.
   PubMed Web of Science ®Google Scholar
• Klawiter EC, Xu J, Naismith RT, et al. Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Mult Scler. 2012;18(9):1259–1268.
   PubMed Web of Science ®Google Scholar
• Combes AJE, Matthews L, Lee JS, et al. Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder. NeuroImage Clin. 2017;16:17–22.
   PubMed Web of Science ®Google Scholar
• Ciccarelli O, Thomas DL, De Vita E, et al. Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica. Ann Neurol. 2013;74(2):301–305.
   PubMed Web of Science ®Google Scholar
• Chien C, Scheel M, Schmitz-Hubsch T, et al. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. Mult Scler. 2019;25(14):1926–1936.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Liu Z, Fukumoto S, et al. Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder. Eur J Neurol. 2020;27(1):92–99.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu A, Chen X, et al. Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy. BMC Neurol. 2014;14(1):246.
   PubMedGoogle Scholar
• Liu Y, Wang J, Daams M, et al. Differential patterns of spinal cord and brain atrophy in NMO and MS. Neurology. 2015;84(14):1465–1472.
   PubMed Web of Science ®Google Scholar
• Liu Y, Duan Y, Huang J, et al. Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. Eur Radiol. 2018;28(1):96–103.
   PubMed Web of Science ®Google Scholar
• Lu P, Tian G, Liu X, et al. Differentiating neuromyelitis optica-related and multiple sclerosis-related acute optic neuritis using conventional magnetic re sonance imaging combined with readout-segmented echo-planar diffusion-weighted imaging. J Comput Assist Tomogr. 2018;42(4):502–509.
   PubMed Web of Science ®Google Scholar
• Buch D, Savatovsky J, Gout O, et al. Combined brain and anterior visual pathways’ MRIs assist in early identification of neuromyelitis optica spectrum disorder at onset of optic neuritis. Acta Neurol Belg. 2017;117(1):67–74.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Nakashima I, Takeshita T, et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016;293:28–33.
   PubMed Web of Science ®Google Scholar
• Naismith RT, Xu J, Tutlam NT, et al. Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology. 2010;74(21):1702–1710.
   PubMed Web of Science ®Google Scholar
• Hadhoum N, Hodel J, Defoort-Dhellemmes S, et al. Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss. Mult Scler. 2016;22(5):649–658.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Moiola L, et al. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic’s neuromyelitis optica. Neurology. 1999;53(8):1705–1710. .
   PubMed Web of Science ®Google Scholar
• Kim SH, Park EY, Park B, et al. Multimodal magnetic resonance imaging in relation to cognitive impairment in neuromyelitis optica spectrum disorder. Sci Rep. 2017;7(1):9180. .
   PubMedGoogle Scholar
• Pichiecchio A, Tavazzi E, Poloni G, et al. Advanced magnetic resonance imaging of neuromyelitis optica: a multiparametric approach. Mult Scler. 2012;18(6):817–824. .
   PubMed Web of Science ®Google Scholar
• Pache F, Zimmermann H, Finke C, et al. Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study. Eur Radiol. 2016;26(12):4413–4422.
   PubMed Web of Science ®Google Scholar
• de Seze J, Blanc F, Kremer S, et al. Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2010;81(4):409–411.
   PubMed Web of Science ®Google Scholar
• Chou IJ, Tanasescu R, Mougin OE, et al. Reduced myelin signal in normal-appearing white matter in neuromyelitis optica measured by 7T magnetic resonance imaging. Sci Rep. 2019;9(1):14378.
   PubMedGoogle Scholar
• Fielding CA, McLoughlin RM, McLeod L, et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Iimmunol. 2008;181(3):2189–2195.
   PubMed Web of Science ®Google Scholar